The Latest

THE LATEST Health

BREAKING NEWS

THE LATEST THINKING

Survival data boosts Merck's Keytruda lead in lung cancer
Photo by: Reuters

(Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

See article

THE LATEST THINKING

The opinions of THE LATEST’s guest contributors are their own.

Searching for TLT's ...

Video Site Tour

The Latest
The Latest

Subscribe to THE LATEST Newsletter.

The Latest
The Latest

Share this story through...

Separate multiple emails with commas. That's not a valid e-mail.